基于加权TOPSIS法的艾迪注射液合理性评价
|
摘要
目的建立本院肿瘤科艾迪注射液使用合理性评价标准,通过加权TOPSIS法对本院肿瘤科艾迪注射液使用情况进行评价,为临床艾迪注射液合理使用提供依据。方法以药品说明书、国家食品药品监督管理总局发布的《中药注射剂临床使用基本原则》作为参考,在查阅相关文献基础上,制定艾迪注射液合理性评价细则。据此评价细则采用加权TOPSIS法对本院2017年下半年的肿瘤科60例艾迪注射液归档病历进行评价。结果评价的60份病历中,相对接近度≥60%的52例(占86.67%),相对接近度在50%~60%的7例(占11.67%),相对接近度在40%~50%的1例(占1.67%)。结论基于加权TOPSIS法制定的艾迪注射液合理性评价将多个因素结合起来,评价结果更加简明扼要、直观可靠;相对传统单个指标评价具有明显的优势。本院肿瘤科艾迪注射液使用较为合理,但仍存在一些不足,应加强管理,保证患者用药更加合理。
Objective To set up weighted TOPSIS method to evaluate Aidi injection in the Oncology Department, and to provide the basis for the rational use of Aidi injection. Methods We formulated the rules to evaluate the rationality of Addi injection base on relevant literatures and drug instructions and basic principles of clinical use of traditional Chinese medicine injection issued by the State Administration of Food and Drugs. The weighted TOPSIS method was used to evaluate the archiving medical records of 60 cases of Aidi injection in our hospital from July to December 2017. Results Among the 60 cases, 52(86.67%) had relative degree of proximity of no less than 60%, 7(11.67%) between 50% to 60%, and 1(1.67%) between 40% to 50%. Conclusion The evaluation of Aidi injection based on the weighted TOPSIS method combines multiple factors that affect the standardized treatment. The use of Aidi injection in the Oncology Department in our hospital is standardized. Thought there are still some deficiencies, we should ensure that patient's medication to be more reasonable by improving management.
Objective To set up weighted TOPSIS method to evaluate Aidi injection in the Oncology Department, and to provide the basis for the rational use of Aidi injection. Methods We formulated the rules to evaluate the rationality of Addi injection base on relevant literatures and drug instructions and basic principles of clinical use of traditional Chinese medicine injection issued by the State Administration of Food and Drugs. The weighted TOPSIS method was used to evaluate the archiving medical records of 60 cases of Aidi injection in our hospital from July to December 2017. Results Among the 60 cases, 52(86.67%) had relative degree of proximity of no less than 60%, 7(11.67%) between 50% to 60%, and 1(1.67%) between 40% to 50%. Conclusion The evaluation of Aidi injection based on the weighted TOPSIS method combines multiple factors that affect the standardized treatment. The use of Aidi injection in the Oncology Department in our hospital is standardized. Thought there are still some deficiencies, we should ensure that patient's medication to be more reasonable by improving management.
引文
[1]徐洁,谢丽艳,戴国梁,等.液相串联质谱同时测定艾迪注射液9种成分[J].中草药,2013,44(5):566-570.
[2]甄玲,李璐,刘吉羊,等. 2012—2016年武汉科技大学附属孝感医院艾迪注射液上市后的安全性再评价[J].现代药物与临床,2017,32(8):1579-1583.
[3]侯金兰,张文艳,刘英宇.吉非替尼片联合艾迪注射液治疗老年非小细胞肺癌的临床研究[J].中国临床药理学杂志,2017,33(20):2013-2015.
[4]陆守荣,温浩,宋惠珠,等.艾迪注射液联合紫杉醇与奥沙利铂化疗治疗老年中晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(18):1660-1662.
[5]许荣龙,何海浪,唐杰,等.艾迪注射液联合放疗治疗非小细胞肺癌的Meta分析[J].中国实验方剂学杂志,2015,21(6):204-209.
[6]张文周,杜娟.艾迪注射液辅助治疗中晚期肺癌近期及远期疗效观察[J].中国医院药学杂志,2015,35(20):1865-1869.
[7]国家食品药品监督管理总局.关于进一步加强中药注射剂生产和临床使用管理的通知[EB/OL].(2008-12-24)[2017-11-15] http://www. sda. gov. cn/WS01/CL0056/35302. Html.
[8]蔡晶,杨雯雯,黄淑琼.加权TOPSIS法在传染病信息报告质量综合评价中的应用[J].现代预防医学,2017,44(27):3941-3944.
[9]刘继斌,曲成毅,王瑞花.基于属性AHM的Topsis综合评价及其应用[J].现代预防医学,2006,33(10):1862-1863.
[10]戚姝娅,李国辉,樊冬鹤,等.艾迪注射液临床应用的适宜性研究[J].中国医院用药评价与分析,2017,17(6):738-741.
[11]孟菲,董利娜.基于文献报道的艾迪注射液不良反应分析[J].中国药物经济学,2015,10(2):148-149.
[12]肖正林. 2012—2015年湘潭市中心医院中药注射剂的使用情况分析[J].现代药物与临床,2017,32(1):134-139.
[13]王小燕,林若飞,宋敏,等.我院125例艾迪注射液用药点评[J].中国药房,2016,27(27):3794-3796.
[14]胡黎川,杨秀斐,苏银法,等. 96例肿瘤患者应用艾迪注射液的回顾性调查[J].医药导报,2012,31(3):383-385.
[15]罗卓卡,张明珠,何丽霞,等.抗肿瘤辅助药艾迪注射液的应用现状及合理性分析[J].安徽医药,2016,20(1):191-192.
[2]甄玲,李璐,刘吉羊,等. 2012—2016年武汉科技大学附属孝感医院艾迪注射液上市后的安全性再评价[J].现代药物与临床,2017,32(8):1579-1583.
[3]侯金兰,张文艳,刘英宇.吉非替尼片联合艾迪注射液治疗老年非小细胞肺癌的临床研究[J].中国临床药理学杂志,2017,33(20):2013-2015.
[4]陆守荣,温浩,宋惠珠,等.艾迪注射液联合紫杉醇与奥沙利铂化疗治疗老年中晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(18):1660-1662.
[5]许荣龙,何海浪,唐杰,等.艾迪注射液联合放疗治疗非小细胞肺癌的Meta分析[J].中国实验方剂学杂志,2015,21(6):204-209.
[6]张文周,杜娟.艾迪注射液辅助治疗中晚期肺癌近期及远期疗效观察[J].中国医院药学杂志,2015,35(20):1865-1869.
[7]国家食品药品监督管理总局.关于进一步加强中药注射剂生产和临床使用管理的通知[EB/OL].(2008-12-24)[2017-11-15] http://www. sda. gov. cn/WS01/CL0056/35302. Html.
[8]蔡晶,杨雯雯,黄淑琼.加权TOPSIS法在传染病信息报告质量综合评价中的应用[J].现代预防医学,2017,44(27):3941-3944.
[9]刘继斌,曲成毅,王瑞花.基于属性AHM的Topsis综合评价及其应用[J].现代预防医学,2006,33(10):1862-1863.
[10]戚姝娅,李国辉,樊冬鹤,等.艾迪注射液临床应用的适宜性研究[J].中国医院用药评价与分析,2017,17(6):738-741.
[11]孟菲,董利娜.基于文献报道的艾迪注射液不良反应分析[J].中国药物经济学,2015,10(2):148-149.
[12]肖正林. 2012—2015年湘潭市中心医院中药注射剂的使用情况分析[J].现代药物与临床,2017,32(1):134-139.
[13]王小燕,林若飞,宋敏,等.我院125例艾迪注射液用药点评[J].中国药房,2016,27(27):3794-3796.
[14]胡黎川,杨秀斐,苏银法,等. 96例肿瘤患者应用艾迪注射液的回顾性调查[J].医药导报,2012,31(3):383-385.
[15]罗卓卡,张明珠,何丽霞,等.抗肿瘤辅助药艾迪注射液的应用现状及合理性分析[J].安徽医药,2016,20(1):191-192.